SPONSOR
IDEAYA Biosciences
Total Trials
2
Recruiting
2
Phases
Phase 3, Phase 1, Phase 2
Conditions studied: Uveal MelanomaSmall-cell Lung CancerNeuroendocrine CarcinomasSolid Tumor Show to Express DLL3
IDEAYA Biosciences is a clinical research sponsor with 2 registered studies on ClinicalTrials.gov, of which 2 are actively recruiting participants. Research covers conditions including Uveal Melanoma, Small-cell Lung Cancer, Neuroendocrine Carcinomas, Solid Tumor Show to Express DLL3.
The trial portfolio spans Phase 3, Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — IDEAYA Biosciences
How many clinical trials has IDEAYA Biosciences sponsored?
ClinicalMetric currently tracks 2 clinical trials sponsored by IDEAYA Biosciences, of which 2 are actively recruiting participants. These trials cover conditions including Uveal Melanoma, Small-cell Lung Cancer, Neuroendocrine Carcinomas. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does IDEAYA Biosciences research focus on?
IDEAYA Biosciences clinical trials span Uveal Melanoma, Small-cell Lung Cancer, Neuroendocrine Carcinomas, Solid Tumor Show to Express DLL3. The research pipeline includes Phase 3, Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a IDEAYA Biosciences clinical trial?
To participate in a IDEAYA Biosciences trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all IDEAYA Biosciences trials with current recruitment status updated daily.
Clinical Trials by IDEAYA Biosciences
NCT07804186 Phase 3
Recruiting
Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma
Uveal Melanoma
NCT07174583 Phase 1, Phase 2
Recruiting
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
Small-cell Lung Cancer
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology